// App-Quantinova.ai

OP010 : Long term efficacy and safety of Ustekinumab for Crohn's disease: results from IM-UNITI long-term extension through 2 years

Researchers

Presenter

  • W. Sandborn

Principal Investigators

  • P. Rutgeerts

  • C. Gasink

  • D. Jacobstein

  • L.-L. Gao

  • J. Johanns

  • B. Sands

  • S.B. Hanauer

  • S. Targan

  • S. Ghosh

  • W.J.S de Villiers

  • J.-F. Colombel

  • B.G. Feagan

Medical Centers

  • University of California San Diego, CA, United States

  • University Hospital Gasthuisberg, Leuven, Belgium

  • Janssen Research and Development, Spring House, PA, United States,

  • Icahn School of Medicine at Mount Sinai, New York, New York, United States

  • Northwestern University, Feinberg School of Medicine, Chicago, IL

  • Cedars Sinai Medical Center, Los Angeles, California, United States

  • University of Birmingham, Birmingham, United Kingdom

  • University of Stellenbosch, Stellenbosch, South Africa

  • Robarts Clinical Trials, Robarts Research Institute, Western University, London, Ontario, Canada

Locations

  • United States

  • Belgium

  • United Kingdom

  • South Africa

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Ustekinumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved